[Federal Register: December 22, 2006 (Volume 71, Number 246)]
[Notices]               
[Page 77063-77064]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22de06-104]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated August 15, 2006, and published in the Federal 
Register on August 22, 2006, (71 FR 48945-48946), Cambrex North 
Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, 
North Brunswick, New Jersey 08902, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)..................  I
Tetrahydrocannabinols (7370)...............  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
4-Methoxyamphetamine (7411)................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Pentobarbital (2270).......................  II
Phenylacetone (8501).......................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
Morphine (9300)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cambrex North Brunswick, Inc. to manufacture the listed basic classes 
of controlled substances is consistent with the public interest at this 
time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification

[[Page 77064]]

of the company's compliance with state and local laws, and a review of 
the company's background and history. Therefore, pursuant to 21 U.S.C. 
823, and in accordance with 21 CFR 1301.33, the above named company is 
granted registration as a bulk manufacturer of the basic classes of 
controlled substances listed.

    Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-21878 Filed 12-21-06; 8:45 am]

BILLING CODE 4410-09-P